Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

Giuseppe Giaccone

doi:10.1080/13543784.2025.2599455

December 5, 2025Expert Opinion on Investigational Drugs

Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

View Full Paper

Ask AI

Bookmark

Share

Key Points

MEK inhibitors show promise in enhancing targeted therapy outcomes for specific cancer types.
Preclinical studies suggest that drug resistance may be mitigated with effective biomarker-guided therapies.
The focus on molecular characterization is critical for developing new therapeutic strategies in oncology.
Further exploration of signal transduction pathways could unveil additional clinical applications for MEK inhibitors.

Implication

Preclinical and clinical studies reveal MEK inhibitors may improve therapeutic strategies in oncology, highlighting molecular characterization importance.

Abstract

While MEK inhibitors in combination with BRAF inhibitors obtained one of the first tumor-agnostic FDA approvals for BRAF V600E/K mutated tumors, additional indications for MEK inhibitors alone have been received in very selected diseases for which molecular characterization is crucial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Giuseppe Giaccone (2025) studied this question.

synapsesocial.com/papers/694022612d562116f28fc937 https://doi.org/10.1080/13543784.2025.2599455

View Full Paper

Ask AI

Bookmark

Share

Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

Key Points

Implication

Abstract

Discussion

Cite This Study

Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading